Crown Reserve Acquisition Corp. I

Current report

We may not be able to complete the Business Combination with Carvix, including in the time required by our amended and restated memorandum and articles of association.

Current report

On March 30, 2026, we entered into the Business Combination Agreement with Merger Sub and Carvix. Consummation of the transactions contemplated by the Business Combination Agreement is subject to a number of conditions, including approval by our stockholders, delivery of the Carvix stockholder written consent, the SEC declaring effective the related Registration Statement on Form S-4, approval for listing on Nasdaq of the shares of common stock to be issued in the transactions, satisfaction of our net tangible asset condition, and our having at the Closing at least the “Minimum Cash Amount,” after giving effect to redemptions, payment of transaction expenses and repayment of indebtedness. There can be no assurance that all such conditions will be satisfied or waived in a timely manner, or at all. If we are unable to complete the Business Combination with Carvix prior to the Outside Date of September 30, 2026 (or such later date as may be mutually agreed by the parties), the Business Combination Agreement may be terminated. If the Business Combination Agreement is terminated and we are unable to identify and consummate an alternative initial Business Combination by November 10, 2026 (or February 10, 2027 if the Combination Period is automatically extended upon execution of an alternative Business Combination agreement), we will be required to cease operations except for the purpose of winding up, redeem all of the public shares, and liquidate.

Current report

The pendency of the Business Combination with Carvix could adversely affect us.

Current report

In connection with the Business Combination Agreement, we are subject to customary covenants regarding the conduct of our business and exclusivity, which limit the scope of activities we may pursue prior to the Closing. The pendency of the proposed Business Combination could divert management’s attention, result in significant transaction expenses, and limit our ability to consider or pursue alternative business combinations. In addition, public stockholders may exercise their redemption rights in connection with the Business Combination, which could materially reduce the funds available to the combined company at the Closing and may impact our ability to satisfy the Minimum Cash Amount condition.

Current report

Following the Domestication, we will be a Delaware corporation, and the rights of our stockholders under Delaware law may differ from those under Cayman Islands law.

Current report

In connection with the Business Combination Agreement, we have agreed to effect a Domestication from a Cayman Islands exempted company to a Delaware corporation prior to the Effective Time. The rights of stockholders under Delaware law differ in certain respects from the rights of shareholders under Cayman Islands law, including with respect to the availability of statutory dissenters’ or appraisal rights, fiduciary duties of directors, indemnification of officers and directors, and the procedures for stockholder votes and consents. Holders of our securities should consider these differences carefully when evaluating the Business Combination.